I+D

I+D

I+D (2)

I+D (2)

I+D (3)

I+D (3)

I+D (4)

I+D (4)

Berenice

Berenice The European Commission has selected a project led by the Vall d’Hebron Research Institute (VHIR), which aims to obtain a more effective drug, with a better cost-benefit relationship and above all, which reduces the side effects of current treatments for Chagas disease.


Imagen9The BERENICE project, an acronym of BEnznidazol and triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE will work on the reformulation of an existing drug, Benznidazol, in order to obtain a safer toxicity profile and an increase in its efficacy. This will therefore mean more affordable access to a curative treatment for a large number of people, a reduction in side effects and finally an impact on the morbidity and mortality related to disease progression.

 

BERENICE has key partners in each of the steps in the scientific, technological and clinical process to ensure its success. The clinical trials will be conducted in the Hospital Universitari Vall d'Hebron (HUVH) and in endemic countries by Doctors Without Borders and the National Administration of Laboratories and Health Institutes 'Dr. Carlos G. Malbran' – National Institute of Parasitology 'Dr. Mario Fatala Chaben' (ANLIS-INP), Argentina. The design of a new nano- or microencapsulated formulation will be undertaken by CIBER-BBN, which is composed of the NANOMOL group from CSIC-ICMAB and the NANOBIOCEL group from the University of the Basque Country. The University of Barcelona (UB) and the Lisbon Institute of Hygiene and Tropical Medicine will contribute their expertise in in vitro tests and toxicity in animal models, respectively, while the preclinical studies in the in vivo model will be conducted by the FIOCRUZ Foundation, Brazil. The sustainability and continuity of the project is guaranteed by the presence of the pharmaceutical industry, through the Praxis laboratory in France and the Elea laboratory in Argentina (Chemo Group), who will be responsible for all matters relating to industrial scale production and the distribution of the new formulations.

Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continúa navegando, consideramos que acepta su uso. Puede obtener más información, o bien conocer cómo cambiar la configuración, en nuestro enlace Políticas de Seguridad. We use our own cookies and third-party cookies to improve our services and show related advertising to your preferences by analyzing their browsing habits. If you continue to browse, consider accepting its use. You can get more information, or how to change the settings in our Política de privacidad.